HIV/AIDS - Will Gene Therapy Provide the Next Breakthrough?

Article Abstract:

Because upwards of 30 percent of newly infected HIV patients have strains resistant to current treatments, new urgency exists for gene therapy research is underway at Oxford Biomedica, Enzo Biochem, GenStar Therapeutics, Cell Genesys, Vical, American Home Products, Gene Shears, VIRxSYS, Children's Hospital in Los Angeles, and Temple University in Philadelphia.

Australia, Vaccines & Antigens for Human Use, Biological Product (except Diagnostic) Manufacturing, Immunology, Biological products exc. diagnostic, Biological products, AHP, Enzo Biochem Inc., ENZ, Wyeth, Oxford BioMedica PLC, GenStar Therapeutics, Cell Genesys Inc., Vical Inc., Gene Shears, VIRxSYS, CEGE, VICL

---

Noteworthy: a rose is a rose

Article Abstract:

Middlesex, UK-based Glaxo Wellcome announced that the FDA Advisory committee had voted agianst recommending Relenza (zanamivir) for the treatment of influenza A and B. One reason for the action was that studying influenza is difficult.

Government regulation (cont), Brief Article

---

Will Pharmacogenomics Change Drug Development?

Article Abstract:

To what extent the new field of pharmacogenomics will have upon drug discover is uncertain, but it holds great potential, and cost benefits too. Drug companies are actively exploring its potential.

Biochemistry, Pharmaceutical Preparations, Drugs, Abstract

Similar abstracts:

• Abstracts: The price of innovation: new estimates of drug development costs. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research
• Abstracts: Medicine and applications. Technology and Products: cervical cancer screening
• Abstracts: Mothers and others: who invests in children's health? The lasting impact of childhood health and circumstance

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.